By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Takeda Pharmaceutical and Sage Bionetworks announced on Thursday a collaboration to identify drug targets for central nervous system diseases.

Under the agreement, Takeda, based in Osaka, Japan, will pay Sage $3.6 million in research funding and fees. Sage will develop a predictive model and identify key regulatory genes and predictive biomarkers in patients with CNS diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.